21.88
+1.2(+5.80%)
Currency In USD
Address
45 Wiggins Avenue
Bedford, MA 01730
United States of America
Phone
781 430 8200
Sector
Healthcare
Industry
Biotechnology
Employees
128
First IPO Date
June 19, 2019
| Name | Title | Pay | Year Born |
| Mr. Ian F. Smith A.C.A., C.P.A. | Interim Chief Executive Officer & Director | 162,308 | 1966 |
| Dr. Adrian R. Krainer Ph.D. | Co-Founder & Independent Director | 45,000 | 1959 |
| Dr. Arthur O. Tzianabos Ph.D. | Interim Executive Chairman | 64,701 | 1963 |
| Mr. Thomas Edward Leggett | Chief Financial Officer | 665,656 | 1977 |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Chief Medical Officer | 726,501 | 1960 |
| Dr. Edward M. Kaye M.D., Ph.D. | Advisor & Director | 1.02M | 1949 |
| Doug Snow | Director of Communications & Investor Relations | 0 | N/A |
| Ms. Dawn Kalmar | Chief Communications Officer | 0 | 1978 |
| Ms. Isabel Aznarez Ph.D. | Co-Founder, Head of Research & Senior Vice President | 0 | 1973 |
| Mr. Jonathan Allan J.D. | Corporate Secretary & General Counsel | 0 | 1990 |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.